Corporate Milestone

2021

Mar
FDA Grants AltruBio AbGn-168H (Neihulizumab) Fast Track Designation in SR-aGVHD

2020

Jun
AbGenomics changes name to AltruBio Inc.
Jan
Dr. Judy Chou, Joins AbGenomics as President & CEO

2018

Mar
FDA Grants Abgenomics AbGn-168H (Neihulizumab) Orphan Drug Designation

2016

Jan
Abgenomics demonstrated the proof of initial efficacy in a Phase-2a clinical trial study of AbGn-168H in patients with psoriatic arthritis.

2015

Feb
AbGn-168H’s phase-II clinical trial targeting psoriasis completed in the United States.

2014

Feb
Phase 2a clinical trial for AbGn-168H completed in the U.S.

2011

Nov
Phase 1 clinical trial of AbGn-168H completed in healthy volunteers.

2006

Jun
Abgenomics International Inc. (AbGUS) formed in the United States.

2002

Jan
Abgenomics developed AbGn-168, a monoclonal antibody treatment for multiple immune diseases and filed a patent application with the USPTO.

2000

Jun
Abgenomics founded.